原发性移植物功能障碍发生率、结局与治疗的当代趋势
多中心前瞻性队列研究纳入2011年8月至2018年6月10个移植中心的1528例肺移植受者,描述体外膜氧合(ECMO)使用趋势及其对原发性移植物功能障碍(PGD)发生率和早期死亡率的影响。PGD发生率为25.7%,年度PGD发生率、LAS中位数及PGD挽救性ECMO使用均上升。PGD与1年死亡率增加相关,挽救性ECMO与死亡率增加显著相关。
要点
- 研究期间年度PGD发生率从14.3%升至38.2%,LAS中位数从38.0升至47.7。
- PGD与1年死亡率增加相关(OR 1.7,95%CI 1.2-2.3,p=.0001)。
- PGD挽救性ECMO与死亡率增加显著相关(OR 1.9,95%CI 1.3-2.7,p=.0007)。
核心结论
- 在现代移植实践中PGD发生率持续上升,同时受者疾病严重程度显著增加。
- 桥接策略使用增加但未影响PGD发生率或死亡率。
- PGD仍与死亡率高度相关,且越来越多地使用挽救性ECMO治疗。
研究设计与样本
- 多中心前瞻性队列研究(肺移植结局组),纳入2011年8月至2018年6月10个移植中心的患者。
- 共纳入1528例受者,PGD定义为基于2016年PGD ISHLT指南的48或72小时3级。
- 采用逻辑回归和生存模型分别对比组间事件(PGD和死亡)及时间-事件(死亡、拔管、出院)结局,模型均容纳潜在混杂因素。
主要发现
- 总PGD发生率为25.7%。
- 年度PGD发生率从14.3%升至38.2%(p=.0002),中位LAS从38.0升至47.7(p=.009),PGD挽救性ECMO使用从5.7%升至20.9%(p=.007)。
- PGD与1年死亡率增加相关(OR 1.7 [95%CI 1.2, 2.3],p=.0001)。
- 桥接策略与非桥接患者相比死亡率无显著差异(p=.66);但PGD挽救性ECMO与死亡率增加显著相关(OR 1.9 [95%CI 1.3, 2.7],p=.0007)。
- 1年限制性平均生存时间比较:合并PGD的静脉-动脉挽救性ECMO受者较无PGD者损失84.1天(比值1.3 [95%CI 1.1, 1.5]),静脉-静脉挽救性ECMO合并PGD者损失27.2天(比值1.1 [95%CI 1.0, 1.4])。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to describe trends in extracorporeal membrane oxygenation (ECMO) use, and define the impact on PGD incidence and early mortality in lung transplantation. METHODS: Patients were enrolled from August 2011 to June 2018 at 10 transplant centers in the multi-center Lung Transplant Outcomes Group prospective cohort study. PGD was defined as Grade 3 at 48 or 72 hours, based on the 2016 PGD ISHLT guidelines. Logistic regression and survival models were used to contrast between group effects for event (i.e., PGD and Death) and time-to-event (i.e., death, extubation, discharge) outcomes respectively. Both modeling frameworks accommodate the inclusion of potential confounders. RESULTS: A total of 1,528 subjects were enrolled with a 25.7% incidence of PGD. Annual PGD incidence (14.3%-38.2%, p = .0002), median LAS (38.0-47.7 p = .009) and the use of ECMO salvage for PGD (5.7%-20.9%, p = .007) increased over the course of the study. PGD was associated with increased 1 year mortality (OR 1.7 [95% C.I. 1.2, 2.3], p = .0001). Bridging strategies were not associated with increased mortality compared to non-bridged patients (p = .66); however, salvage ECMO for PGD was significantly associated with increased mortality (OR 1.9 [1.3, 2.7], p = .0007). Restricted mean survival time comparison at 1-year demonstrated 84.1 days lost in venoarterial salvaged recipients with PGD when compared to those without PGD (ratio 1.3 [1.1, 1.5]) and 27.2 days for venovenous with PGD (ratio 1.1 [1.0, 1.4]). CONCLUSIONS: PGD incidence continues to rise in modern transplant practice paralleled by significant increases in recipient severity of illness. Bridging strategies have increased but did not affect PGD incidence or mortality. PGD remains highly associated with mortality and is increasingly treated with salvage ECMO.
引用
- Cantu E, Diamond JM, Cevasco M, et al. Contemporary trends in PGD incidence, outcomes, and therapies. J Heart Lung Transplant. 2022. PMID: 36216694. doi:10.1016/j.healun.2022.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。